Rho Kinase-Mediated Vasoconstriction Is Important in Severe Occlusive Pulmonary Arterial Hypertension in Rats
暂无分享,去创建一个
N. Voelkel | K. Morris | M. Oka | I. McMurtry | L. Taraseviciene‐Stewart | N. Homma | N. Burns | D. Kraskauskas | Donatas Kraskauskas
[1] P. Insel,et al. Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: role for PDE1. , 2007, American journal of physiology. Lung cellular and molecular physiology.
[2] Ruopeng Sun,et al. Long-term inhibition of Rho kinase with fasudil attenuates high flow induced pulmonary artery remodeling in rats. , 2007, Pharmacological research.
[3] C. Ricachinevsky,et al. Treatment of pulmonary arterial hypertension. , 2006, Jornal de pediatria.
[4] N. Voelkel,et al. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. , 2006, American journal of physiology. Lung cellular and molecular physiology.
[5] M. Walsh. The force is with α‐actinin: dynamic regulation of the extracellular matrix‐cytoskeletal connection in airway smooth muscle , 2006 .
[6] K. Morris,et al. Involvement of RhoA/Rho kinase signaling in pulmonary hypertension of the fawn-hooded rat. , 2006, Journal of applied physiology.
[7] Christopher G Sobey,et al. Targeting Rho and Rho-kinase in the treatment of cardiovascular disease. , 2006, Trends in pharmacological sciences.
[8] L. Shimoda,et al. Mechanisms of endothelin-1-induced contraction in pulmonary arteries from chronically hypoxic rats. , 2006, American journal of physiology. Lung cellular and molecular physiology.
[9] T. Nakano,et al. Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. , 2006, Circulation journal : official journal of the Japanese Circulation Society.
[10] M. Walsh. The force is with alpha-actinin: dynamic regulation of the extracellular matrix-cytoskeletal connection in airway smooth muscle. , 2006, The Journal of physiology.
[11] A. Takeshita,et al. Rho-kinase is an important therapeutic target in cardiovascular medicine. , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[12] S. Groshong,et al. Pulmonary hypertension: cellular and molecular mechanisms. , 2005, Chest.
[13] P. Pacaud,et al. Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension , 2005, British journal of pharmacology.
[14] A. Zaiman,et al. One hundred years of research in the pathogenesis of pulmonary hypertension. , 2005, American journal of respiratory cell and molecular biology.
[15] P. McLoughlin,et al. Inhibition of Rho-Kinase Attenuates Hypoxia-Induced Angiogenesis in the Pulmonary Circulation , 2005, Circulation research.
[16] J. Wharton,et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. , 2005, American journal of respiratory and critical care medicine.
[17] M. Humbert,et al. Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension , 2005, Circulation.
[18] H. Shimokawa,et al. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. , 2005, American journal of respiratory and critical care medicine.
[19] A. Takeshita,et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension , 2005, Heart.
[20] B. Walker,et al. Chronic hypoxia augments protein kinase G-mediated Ca2+ desensitization in pulmonary vascular smooth muscle through inhibition of RhoA/Rho kinase signaling. , 2004, American journal of physiology. Lung cellular and molecular physiology.
[21] K. Murthy,et al. Gq/G13 signaling by ET-1 in smooth muscle: MYPT1 phosphorylation via ETA and CPI-17 dephosphorylation via ETB. , 2004, American journal of physiology. Cell physiology.
[22] K. Morris,et al. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. , 2004, American journal of physiology. Lung cellular and molecular physiology.
[23] M. Oka,et al. Rho/Rho kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats. , 2004, American journal of physiology. Lung cellular and molecular physiology.
[24] M. Humbert,et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.
[25] K. Kaibuchi,et al. Long-Term Treatment With a Rho-Kinase Inhibitor Improves Monocrotaline-Induced Fatal Pulmonary Hypertension in Rats , 2004, Circulation research.
[26] A. Branzi,et al. The endothelin system in pulmonary arterial hypertension. , 2004, Cardiovascular research.
[27] A. Somlyo,et al. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. , 2003, Physiological reviews.
[28] M. Maclean,et al. Increased expression of the cGMP‐inhibited cAMP‐specific (PDE3) and cGMP binding cGMP‐specific (PDE5) phosphodiesterases in models of pulmonary hypertension , 2002, British journal of pharmacology.
[29] John H. Zhang,et al. Mechanism of RhoA/Rho kinase activation in endothelin-1- induced contraction in rabbit basilar artery. , 2002, American journal of physiology. Heart and circulatory physiology.
[30] T. Kobayashi,et al. Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage. , 2001, Life sciences.
[31] N. Sugimoto,et al. Rho activation in excitatory agonist-stimulated vascular smooth muscle. , 2001, American journal of physiology. Cell physiology.
[32] G. Pfitzer. highlighted topics Signal Transduction in Smooth Muscle Invited Review: Regulation of myosin phosphorylation in smooth muscle , 2022 .
[33] R. Paul,et al. Distinct Pathways of Ca2+ Sensitization in Porcine Coronary Artery : Effects of Rho-Related Kinase and Protein Kinase C Inhibition on Force and Intracellular Ca2+ , 2001 .
[34] R. Paul,et al. Distinct Pathways of Ca 2+ Sensitization in Porcine Coronary Artery: Effects of Rho-Related Kinase and Protein Kinase C Inhibition on Force and Intracellular Ca 2+ , 2001, Circulation research.
[35] N. Voelkel,et al. Severe pulmonary hypertension after the discovery of the familial primary pulmonary hypertension gene. , 2001, The European respiratory journal.
[36] P. Hirth,et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death‐dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[37] K. Kaibuchi,et al. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. , 2001, Trends in pharmacological sciences.
[38] N. Voelkel,et al. Hypoxia-induced pulmonary vascular remodeling: a model for what human disease? , 2000, The Journal of clinical investigation.
[39] A. Evans,et al. Inhibition of sustained hypoxic vasoconstriction by Y‐27632 in isolated intrapulmonary arteries and perfused lung of the rat , 2000, British journal of pharmacology.
[40] P. Macdonald,et al. Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. , 2000, Circulation.
[41] K. Kaibuchi,et al. The COOH Terminus of Rho-kinase Negatively Regulates Rho-kinase Activity* , 1999, The Journal of Biological Chemistry.
[42] T. Hayama,et al. Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist. , 1999, The Journal of pharmacology and experimental therapeutics.
[43] Shuh Narumiya,et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension , 1997, Nature.
[44] T. Cheng. Endothelin receptor antagonists. , 1997, Circulation.
[45] M. Pasque,et al. Single lung transplantation for pulmonary hypertension. Single institution experience in 34 patients. , 1995, Circulation.
[46] N. Tanabe,et al. Structural and transport properties of biaxially aligned YBa2Cu3O7−x films on polycrystalline Ni‐based alloy with ion‐beam‐modified buffer layers , 1993 .
[47] M. Oka,et al. EDRF suppresses an unidentified vasoconstrictor mechanism in hypertensive rat lungs. , 1993, The American journal of physiology.
[48] M. Zamora,et al. Pulmonary and systemic vascular responsiveness to TNF-alpha in conscious rats. , 1993, Journal of applied physiology.
[49] M. Pasque,et al. Single‐Lung Transplantation for Pulmonary Hypertension: Three‐Month Hemodynamic Follow‐up , 1991, Circulation.
[50] E H Bergofsky,et al. Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .
[51] B. Groves,et al. The case for treatment of selected patients with primary pulmonary hypertension. , 1986, The American review of respiratory disease.